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Background: Mice with functional ablation of the neurokinin-1 receptor gene (NK1R−/−) display behavioural
abnormalities which resemble the hyperactivity, inattention and impulsivity seen in Attention Deﬁcit Hyperac-
tivity Disorder (ADHD). Here, we investigatedwhether the established ADHD treatment, atomoxetine, alleviates
these abnormalities when tested in the light/dark exploration box (LDEB) and 5-Choice Serial Reaction-Time
Task (5-CSRTT).
Methods: Separate cohorts ofmicewere tested in the 5-CSRTT and LDEB after treatmentwith no injection, vehicle
or atomoxetine (5-CSRTT: 0.3, 3 or 10 mg/kg; LDEB: 1, 3 or 10 mg/kg).
Results: Atomoxetine reduced the hyperactivity displayed by NK1R−/− mice in the LDEB at a dose (3 mg/kg)
which did not affect the locomotor activity of wildtypes. Atomoxetine (10 mg/kg) also reduced impulsivity in
NK1R−/−mice, but not wildtypes, in the 5-CSRTT. No dose of drug affected attention in either genotype.
Conclusions: This evidence that atomoxetine reduces hyperactive/impulsive behaviours inNK1R−/−mice consol-
idates the validity of using NK1R−/−mice in research of the aetiology and treatment of ADHD.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Atomoxetine (Strattera®: atomoxetine hydrochloride) is a preferen-
tial noradrenaline reuptake inhibitor, which inhibits the noradrenaline
(NAT), serotonin (SERT) and dopamine (DAT) transporters with Ki values
of 5, 77 and 1451 nM, respectively (Bymaster et al., 2002). Although the
drug was ﬁrst developed as an antidepressant, it is now an approved
treatment for Attention Deﬁcit Hyperactivity Disorder (ADHD) (Preti,
2002) and is marketed as a non-psychostimulant alternative to the ﬁrst-
line ADHD treatments, amphetamine and methylphenidate.
ADHD is characterised by three core abnormalities: excessive
impulsivity, inattention and hyperactivity. Mice lacking functional
neurokinin-1 receptors (NK1R−/−) typically display ADHD-like inatten-
tion and impulsivity when tested in the 5-Choice Serial Reaction-Time
Task (5-CSRTT) (Yan et al., 2011). They are also hyperactive in a number
of procedures (Fisher et al., 2007; Herpfer et al., 2005; Yan et al., 2010).
Moreover, low doses of NK1R antagonists induce hyperactivity in
wildtype mice (Yan et al., 2010) and exacerbate inattention and
impulsivity in the 5-CSRTT (Weir et al., 2014).y Disorder; 5-CSRTT, 5-Choice
x;NK1R,Neurokinin-1receptor;
. This is an open access article underThe ADHD treatments, amphetamine, methylphenidate and
guanfacine, all reduce the hyperactivity of these mice (Pillidge et al.,
2014; Yan et al., 2010). Although amphetamine did not reduce the
impulsivity/inattention displayed by NK1R−/− mice in the 5-CSRTT,
the non-stimulant guanfacine, did (Pillidge et al., 2014; Yan et al.,
2011). The proposal that thesemice could beused to study the aetiology
of ADHD-like behaviours in vivo is supported by evidence that TACR1
(the human equivalent of the NK1R gene) polymorphisms are associat-
ed with ADHD (Sharp et al., 2009, 2014; Yan et al., 2010).
The effects of atomoxetine in the 5-CSRTT in outbred rodents are
remarkably consistent. In Long Evans and Lister-hooded rats, this drug
reduces premature responses (impulsivity) (Fernando et al., 2012;
Paterson et al., 2011; Robinson, 2012; Robinson et al., 2008) but has
negligible effects on omissions (inattention). The same pattern has
even been reported in zebraﬁsh performing a modiﬁed version of the
5-CSRTT: atomoxetine attenuated premature responses, whereas omis-
sions were unaffected (Parker et al., 2014). However, whenever
atomoxetine does increase omissions, this is generally paralleled by
increased response latencies (Baarendse and Vanderschuren, 2012;
Sun et al., 2012), suggesting a drug effect on arousal or motivation to
carry out the task.
Our aim in these experiments was to explore further the use of
NK1R−/− mice as a preclinical resource for investigating ADHD-like
behaviour. To that end, we investigated whether atomoxetine amelio-
rates hyperactivity of NK1R−/− mice and/or deﬁcits in their cognitivethe CC BY license (http://creativecommons.org/licenses/by/3.0/).
57K. Pillidge et al. / Pharmacology, Biochemistry and Behavior 127 (2014) 56–61performance, in the light–dark exploration box (LDEB) and 5-CSRTT,
respectively.
2. Methods
2.1. Ethics statement
All experiments were authorised under the Animals (Scientiﬁc
Procedures) Act, 1986 (UK) and were approved by the Ethical Review
Panel at University College London. This report was written in concor-
dance with the ARRIVE guidelines for animal experiments (Kilkenny
et al., 2010).
2.2. Drugs
Tomoxetine (atomoxetine) hydrochloride was purchased from
Sigma Aldrich, UK, dissolved in 0.9% saline and injected intraperitoneal-
ly (i.p.) in a volumeof 10 mL/kg. Doses of 1, 3 and 10 mg/kgwere tested
in the LDEB,with eachmouse testedwith onedose, only. In the5-CSRTT,
doses of 0.3, 3 and 10 mg/kgwere tested at once-weekly intervals in the
same animals, with every animal receiving each dose once.
2.3. Animals
NK1R−/− mice and their wildtype counterparts were bred at Uni-
versity College London in a facility held at 21± 2 °C, 45± 5% humidity,
with a 12:12 h light: dark cycle (07.00–19.00 h). The home-cages incor-
porated environmental enrichment (cardboard tunnels and nesting
material (LBS Biotechnology, UK)) and were cleaned twice-weekly
(bedding obtained from Litaspen Premium (Lillico)). Rodent chow
was obtained from Harlan UK (2018 global Rodent Diet). All the mice
derived from inbred homozygous strains (see: Yan et al., 2010;
Pillidge et al., 2014) and were of a 129/Sv × C57BL/6J background,
backcrossed with an outbred MF1 strain many generations ago (de
Felipe et al., 1998).
2.4. Light/dark exploration box
NK1R−/− and wildtype mice, from inbred homozygous lines, were
used to enable comparison of the results of this study with those from
our previously published reports (Dudley et al., 2013; Pillidge et al.,
2014; Yan et al., 2010). Both genotypes were tested in the light/dark
exploration box (LDEB) after either no injection (NI), or administration
of vehicle (0.9% saline, 10 mL/kg) or atomoxetine (1, 3 or 10 mg/kg, i.p.)
(N=5 per group). The choice of drug doses was informed by published
reports of its effects on the behaviour of rodents (e.g. (rat) Robinson
et al., 2008; (mouse) Balci et al., 2008). The LDEB also served as a
dose-range study to determine the most appropriate doses to use in
the 5-CSRTT. Treatmentswere allocated in a counterbalanced sequence,
with each mouse receiving only one treatment. One wildtype and one
NK1R−/− mouse were always tested simultaneously, with the same
treatment, in adjacent LDEBs. The procedure is described fully in
Fisher et al. (2007) and Herpfer et al. (2005). In brief, the mice were
habituated to the test room for at least 3 h and then conﬁned, individu-
ally, to the dark zone (4 lx) of the LDEB for 60 min, after which they
were injected with their allocated treatment, or left untreated and,
replaced in the dark zone for a further 30 min. After a total of 90 min
in the dark zone, the mice were transferred, individually, to the light
zone (20 lx) and allowed to commute freely between the two zones.
Their behaviour was recorded by a digital video camera and scored
later by a blinded observer. The ﬁrst 10 min of activity after transfer to
the light zone was used in the statistical analysis. One NK1R−/−
mouse from the vehicle group was excluded from the analysis, because
it was an outlier in nearly every behavioural measure.2.5. 5-Choice Serial Reaction-Time Task (5-CSRTT)
The 5-CSRTT protocol followed that detailed previously (Yan et al.,
2011). This 5-CSRTT studywas part of a larger experiment investigating
whether the behavioural phenotype of adult mice was inﬂuenced by
breeding strategy. This involved a comparison of the behaviour of
homozygous wildtype (NK1R+/+) and NK1R−/− progeny of inbred
homozygous parents (‘homs’) with the same genotypes bred from
heterozygous (NK1R+/−) breeding pairs (‘hets’). Wildtype and
NK1R−/− homs were housed separately, but het mice were housed in
cages that contained at least one wildtype and one NK1R−/− mouse.
Each home-cage contained 2–4 mice. 12 wildtype male and 12
NK1R−/− male mice were used at 6–8 weeks of age (weighing WT
hom: 26.5–33.5 g, NK1R−/− hom: 28.3–32.8 g, WT het: 29.9–36.0 g,
NK1R−/− het: 29.5–35.7 g) at the start of training.
The mice were brought into the laboratory on weekdays between
09.00 and 09.30 h and weighed before training/testing in the 5-CSRTT
between 10.00 h and 12.00 h (AM session) or 13.00 h and 15.00 h
(PM session). Mice were fed, after the 5-CSRTT sessions had ended,
with a quota of food adjusted to maintain subjects at 90% of their
original free-feeding body weight. Water was available ad libitum.
The apparatus (Med Associates, St. Albans, VT, USA) comprised
sound-attenuated operant chamberswith ﬁve equally-spaced apertures
incorporated into one wall. Apertures could be illuminated indepen-
dently and mouse ‘nose-pokes’ into the apertures interrupted infrared
beams, which enabled scoring of correct, incorrect, premature and
perseverative responses. Omitted responses were scored when no
nose-poke occurred. Correct responses were rewarded with sweetened
milk (0.01 mL of 30% condensed milk solution), delivered into a
magazine in the opposite wall. Collection of the reward (nose-pokes
into the magazine) initiated the next trial. Incorrect, omitted and
premature responses were punished with a 5 s time-out, during
which the house-light was extinguished and no new trial could be
initiated. Perseverative responses were not punished.
Mice were assigned to one of four test chambers in a fully
counterbalanced design andwere tested in the same chamber through-
out. They were ﬁrst habituated to the apparatus before graduating
through increasingly challenging stages of training (see: Yan et al.,
2011 for the criteria for each stage). After reaching a stable baseline at
Stage 6, for 3 consecutive days, mice qualiﬁed for drug testing. They
were tested with a variable inter-trial interval (VITI; 2, 5, 10 or 15 s, de-
livered on a random schedule) onceweekly, on Fridays, only if they had
maintained a stable baseline of responding in the intervening Tuesday–
Thursday training sessions. VITI testswere used, rather thanunexpected
prolongation of the ITI, because the former prevents the strategic use of
interval-timing, thereby increasing the required cognitive effort. The
ﬁrst week of testing was carried out with treatment-naïve mice to
compare the baseline performance of the two genotypes from the two
breeding colonies (no -injection 1: ‘NI-1’, to be reported in full
elsewhere).
Over the following 5 weeks, mice were tested 30min after an injec-
tion of either vehicle (saline, 10 mL/kg), or atomoxetine (0.3, 3 or
10 mg/kg), or after another ‘no-injection’ session (‘NI-2’). This NI-2
session served as a control for any effects of repeated testing on baseline
performance (see: Weir et al., 2014). The doses of atomoxetine used in
this experiment were based on the ﬁndings from the LDEB: speciﬁcally,
a lower dose (0.3 mg/kg) replaced the 1 mg/kg dose, used in the LDEB,
in order to test whether any cognitive effects of the drug could be disso-
ciated from a reduction in locomotor activity. Eachmouse received each
treatment once, only. The sessions were counterbalanced across
subjects, using a pseudo William's Latin-square, to account for any
effects of repeated testing and potential nuisance factors (e.g. time of
day: see Weir et al. (2014) and Yan et al. (2011)). Test sessions lasted
for 45 min, or 100 trials, whichever occurred ﬁrst. Two wildtypes (one
hom and one het) and one NK1R−/− (hom) mouse failed to graduate
through training in the 5-CSRTT, and were not tested.
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Statistical analyses were performed, using InVivoStat (Clark et al.,
2012), on raw or transformed data (arcsine, log10 or square-root):
whichever optimised the homogeneity of variance in the ‘predicted
versus residuals’ plot in InVivoStat. The ‘normal probability plot’ was
used to determine whether or not the data were normally distributed.
If not, a rank transformation was applied: i.e. the data were assigned
ranks, as for a non-parametric analysis, which were subjected to
parametric tests.
In the LDEB, two-way ANOVAs were performed on raw or trans-
formed data, with the main factors ‘Genotype’ and ‘Treatment’. First,
the ANOVA compared the factors across all groups (uninjected, vehicle
and drug-treated). If there was amain effect of either factor, or an inter-
action between them, further analyses were carried out using post hoc
ANOVA to compare vehicle controls with drug treatment (main effect
of ‘Drug’). LSD tests were used as further post hoc comparisons of
individual groups.
Repeated-measures analyses were used to examine data from the
5-CSRTT. These used a mixed model approach: ‘Genotype’ and ‘Colo-
ny’ were ﬁrst used as between-subjects factors and ‘Drug’ was the
within-subjects factor. There was no interaction between Colony
and Drug for any variable and so the groups for the ‘Colony’ factor
were collapsed. ‘Time of day’ (i.e. AM session/PM session) was also
investigated because previous studies indicated that this can inﬂu-
ence behaviour in the 5-CSRTT (Weir et al., 2014; Yan et al., 2011).
When Time of day had a main effect, or interacted with genotype, it
was used as a blocking factor, to account for any additional variance
in the data. This was valid since there were no Time of day ∗ Drug
interactions for any dependent variable (i.e. drug treatment had
the same effect on behaviour regardless of Time of day). When
there were no effects of Time of day, this factor was collapsed across
all subjects. A main effect of ‘Genotype’ or ‘Drug’, or an interaction
between them, was used as the criterion for carrying out post hoc
pairwise comparisons.Fig. 1. Theeffects of atomoxetine (1, 3 and 10 mg/kg, i.p.), vehicle (saline) or no injection (NI) onA
of returns to the light zone andD: latency to leave the light zone inwildtype (white bars) andNK
versus vehicle within genotype. Lines linking bars indicate statistical signiﬁcance of P b 0.05. N =3. Results
3.1. Atomoxetine reduces motor activity in wildtype and NK1R−/− mice
(Fig. 1)
Uninjected NK1R−/− mice were hyperactive in the light zone
[[RAW]geno: F(1,15) = 13.69, P = 0.002, WT vs. KO, NI: P = 0.004,
Fig. 1A] and vehicle-treated NK1R−/− mice were hyperactive in the
dark zone [[RAW]geno: F(1,15) = 7.06, P = 0.018, WT vs. KO, VEH:
P = 0.044, Fig. 1B].
Atomoxetine reduced the activity of mice of both genotypes in the
light zone [[RAW]drug: F(3,31) = 3.84, P = 0.019] and dark zone
[[LOG10]drug: F(3,29) = 4.69, P = 0.009]. Speciﬁcally, the mid-range
dose of atomoxetine (3 mg/kg) reduced the activity of NK1R−/−mice,
but not wildtypes, in the light [KO VEH vs. ATX3: P = 0.039] and dark
zones [KO VEH vs. ATX 3: P = 0.003]. However, the higher dose
(10 mg/kg) reduced locomotor activity of both genotypes in both
zones [light: VEH vs. ATX10, WT: P = 0.043, KO: P = 0.023; dark:
VEH vs. ATX10, WT: P = 0.039, KO: P = 0.021], compared to vehicle.
Atomoxetine also caused an overall reduction in the number of
returns to the light zone [[LOG10]drug: F(3,31) = 4.13, P = 0.014,
Fig. 1C], across both genotypes [[LOG10]drug ∗ geno: F(3,31) = 1.66,
P = 0.196]. However, pairwise comparisons revealed that this reduc-
tion was evident only in NK1R−/−mice at 3 mg/kg [KO VEH vs. ATX3:
P = 0.008] and 10 mg/kg [KO VEH vs. ATX10: P = 0.001]. The number
of returns to the light zone (a measure of passive avoidance) by
wildtypes was not reduced by any dose of drug. Across all doses,
atomoxetine had no effect on the latency to leave the light zone (active
avoidance) [[LOG10]drug: F(3,29) = 1.78, P = 0.174, Fig. 1D], but just
missed the statistical criterion for increasing the latency of NK1R−/−
mice at 3 mg/kg [KO VEH vs. ATX3: P = 0.078]. However, a genotype
difference [[LOG10]geno: F(3,29) = 6.68, P = 0.015] was evident at
3 mg/kg [ATX3, WT vs. KO: P = 0.021]. Atomoxetine had no effect on
time spent in the light zone [[RAW]drug: F(3,31) = 0.09, P = 0.964
(data not shown)].: activity per unit time in the light zone, B: activity per unit time in the dark zone, C: number
1R−/−mice (grey bars) in the light–dark exploration box. Data showmean± SEM. *P b 0.05
5.
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not wildtypes
In this experiment, NK1R−/−mice did not display an impulsive phe-
notype: i.e. therewas nodifference between the genotypes in the rate of
premature responding overall [[SQRT]geno: F(1,13) = 0.44, P = 0.520,
Fig. 2A] or at baseline (NI-2) [WT vs. KO: P = 0.336]. Across all doses,
atomoxetine caused a reduction in %premature responses [[SQRT]drug:
F(3,55) = 2.89, P = 0.044], which did not depend on genotype [[SQRT]
drug ∗ geno: F(3,55) = 0.76, P = 0.521]. Nevertheless, post hoc analysis
revealed that the drug reduced premature responses by NK1R−/−mice,
only, at 10 mg/kg [KO, VEH vs. ATX10: P = 0.006].
3.3. Atomoxetine prolongs the latency to reward, but not latency to correct
response
Wildtype andNK1R−/−mice took the same length of time to respond
correctly [[RANK]geno: F(1,19) = 0.60, P = 0.448, Fig. 2B] and to reach
the magazine, overall [[RANK]geno: F(1,19) = 0.74, P = 0.400, Fig. 2C].
Atomoxetine increased the latency to magazine [[RANK]drug: F(3,55) =
10.59, P b 0.001]: this affected both genotypes at the two higher doses
[VEH vs. ATX3, WT: P = 0.033, KO: P b 0.001; VEH vs. ATX10, WT:
P b 0.001, KO: P b 0.001]. However, the drug had no effect on the latency
to correct response [[RAW]drug: F(4,74)= 1.85, P= 0.128]. Anothermea-
sure of motivation, the number of trials completed (Table 1), was unaf-
fected by either genotype [[ARCSINE]geno: F(1,13) = 0.89, P = 0.363]
or drug [[ARCSINE]drug: F(4,51) = 0.89, P = 0.479].
3.4. Atomoxetine has no effect on accuracy, omission errors or perseveration
Time of day affected %accuracy, %omissions and perseveration, but
there was no interaction with drug treatment, so ‘time of day’ was used
as a blocking factor in the analysis of these behaviours. There was no
overall genotype difference in %omissions [[SQRT] geno: F(1,18) = 0.03,Fig. 2.A: The effects of atomoxetine (0.3, 3 and 10 mg/kg, i.p.) onA: %premature responses, B: la
(saline) and no injection (NI-2), inwildtype (white bars) andNK1R−/−mice (grey bars). Data sh
indicates P b 0.05 versus vehicle within genotype.P = 0.865, Fig. 2D], %accuracy [[RAW]geno: F(1,18) = 0.06, P = 0.816,
Table 1] or perseveration [LOG10]geno: F(1,18) = 0.00, P = 0.979,
Table 1]. Moreover, atomoxetine had no effect on any of these behaviours
[%accuracy: [RAW] F(4,74) = 0.24, P = 0.914; %omissions [SQRT] F(4,74) =
0.27, P = 0.897; perseveration [LOG10] F(4,74) = 0.99, P = 0.418].
4. Discussion
Here we report that atomoxetine reduced ADHD-like hyperactive/
impulsive behaviours in NK1R−/− mice, at doses that did not affect
wildtypes. Although interactions between genotype and drug were
not statistically signiﬁcant, post-hoc comparisons revealed that
NK1R−/− mice were more sensitive to this drug and/or responded
more consistently than the wildtypes. The ﬁndings broadly replicate
those reported on tests of this drug in outbred rats performing the 5-
CSRTT. However, to the best of our knowledge, this is the ﬁrst study,
using the 5-CSRTT, to ﬁnd that atomoxetine is more effective in rodents
expressing behavioural abnormalities, analogous to those seen in ADHD
patients, than in wildtypes.
4.1. Atomoxetine prevents hyperactivity
Uninjected NK1R−/−mice were hyperactive in the light zone of the
LDEB, but this was not evident after they had experienced an i.p.
injection. Interestingly, the reverse was observed in the dark zone. The
reason for this is not clear, but inﬂuences of the functional status of
NK1R on the response to stress have been well documented (for
reviews see: Ebner and Singewald, 2006; Stanford, 2014).
Atomoxetine reduced the locomotor hyperactivity displayed by
NK1R−/− mice in the LDEB at a dose (3 mg/kg) that did not affect
wildtypes. Despite a reduction in the number of returns to the light
zone (increased passive avoidance), this reduction in locomotor activity
response is unlikely to be explained by an increase in anxiety-like
behaviour (see: Stanford, 2007) because there was a concomitanttency tomagazine, C: latency to correct response andD:%omissions comparedwith vehicle
owmean±SEM.N= 9–11. Lines linking bars indicate statistical signiﬁcance of P b 0.05, *
Table 1
The effects of atomoxetine on behaviour of NK1R−/− (‘KO’) and wildtype (‘WT’) mice in the 5-CSRTT. Values show mean ± SEM. N = 9–11 per group.
No injection Vehicle Atomoxetine 0.3 mg/kg Atomoxetine 3 mg/kg Atomoxetine 10 mg/kg
Behaviour WT KO WT KO WT KO WT KO WT KO
Total number of trials 100.0 ± 0 100.0 ± 0 100.0 ± 0 100.0 ± 0 100.0 ± 0 100.0 ± 0 100.0 ± 0 100.0 ± 0 99.6 ± 0.4 99.2 ± 0.6
%Accuracy 97.5 ± 0.85 97.2 ± 0.86 96.9 ± 1.00 97.3 ± 0.56 97.3 ± 1.02 97.4 ± 0.57 98.0 ± 0.79 97.8 ± 0.51 97.1 ± 1.07 97.2 ± 0.77
Perseveration (per
100 trials)
12.3 ± 3.51 12.1 ± 4.05 12.2 ± 3.78 17.3 ± 7.00 19.1 ± 11.57 13.1 ± 4.15 12.3 ± 4.86 10.5 ± 3.86 17.2 ± 6.49 15.6 ± 5.23
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this dose. Moreover, there was no change in the time in the light zone,
which would be expected if there was an appreciable effect on animals'
emotionality.
The genotype difference in the locomotor response to atomoxetine
is consistent with its effects in other rodent models of ADHD, including
spontaneously hypertensive (SHR) rats, trimethyltin chloride-treated
(TMT) rats (Tamburella et al., 2012) and 6-OHDA-lesioned rats
(Moran-Gates et al., 2005), but is at odds with a report that the drug
did not affect hyperactive DAT-KO mice (Del'Guidice et al., 2014).
Also, it is striking that NK1R−/− mice were more sensitive to the α2-
adrenoceptor agonist, guanfacine, in this test (Pillidge et al., 2014).
4.2. Atomoxetine reduces impulsivity
Unlike our previous studies (Dudley et al., 2013; Pillidge et al., 2014;
Yan et al., 2011), NK1R−/−mice did not display an excessively impul-
sive phenotype at baseline (NI-2) in this study. This is likely to be be-
cause premature responses of NK1R−/− mice dissipate on repeated
testing (Weir et al., 2014). Also, this behaviour seems to be inﬂuenced
by an interaction between NK1Rs and environmental/epigenetic factors
arising from the breeding strategy (to be reported elsewhere). Never-
theless, atomoxetine (10 mg/kg) reduced premature responses by
NK1R−/− mice, regardless of breeding strategy, but had no effect in
wildtypes. However, an increase in the latency to magazinewas evident
in both genotypes, suggesting that different mechanisms regulate these
two behaviours. Importantly, neither of these behavioural changes is
likely to be explained by any drug induced reduction in appetite, or
other motivation to carry out the task, because there was no corre-
sponding increase in %omissions or latency to correct response, which
are well-established measures of motivation.
These results are supported by consistent reports that atomoxetine
reduces impulsivity in outbred Lister-hooded rats performing the 5-
CSRTT (Baarendse and Vanderschuren, 2012; Robinson et al., 2008), es-
pecially in animals that display high impulsivity at baseline (i.e. High
Impulsive (HI) rats) (Blondeau and Dellu-Hagedorn, 2007; Fernando
et al., 2012; Tomlinson et al., 2014). Moreover, atomoxetine is more ef-
fective when impulsivity is increased bymanipulating the task parame-
ters: for example, by extending the inter-trial interval (ITI) (Baarendse
and Vanderschuren, 2012; Paterson et al., 2011). However, Robinson
(2012) also reports that atomoxetine is efﬁcacious under baseline con-
ditions and when the task is made more difﬁcult (e.g. by reducing the
stimulus duration or adding a distracter stimulus). To date, only one
study has examined the effect of atomoxetine in the SHR (the most ex-
tensively characterised rodent model of ADHD) in the 5-CSRTT
(Dommett, 2014). Atomoxetine (0.1–5 mg/kg) did not affect any be-
havioural measure at any dose, but the protocol used in that study dif-
fered substantially from that used here.
Although we have not studied the mechanisms underlying these
behavioural responses to atomoxetine, our earlier study similarly
revealed a genotype difference in sensitivity to guanfacine in the
same behavioural tests (Pillidge et al., 2014). This suggests a
genotype difference in regulation of noradrenergic transmission,
possibly mediated by α2-adrenoceptors: a proposal supported by
neurochemical evidence (Fisher et al., 2007; Herpfer et al., 2005,
see also: Stanford, 2014). If so, it is not surprising that the effects ofatomoxetine, which has a high and selective afﬁnity for the nor-
adrenaline transporter, and for which changes in extracellular trans-
mitter depend on neuronal ﬁring-rate (i.e. are impulse dependent:
Bymaster et al., 2002), differ in NK1R−/− and wildtype mice. This
possibility that the noradrenergic response to atomoxetine differs
in NK1R−/− and wildtype mice merits further research. However,
in light of evidence that NK1R inﬂuence the permeability of the
blood brain barrier (Harford-Wright et al., 2014), a pharmacokinetic
explanation is also possible.
Although atomoxetine preferentially inhibits the noradrenaline
transporter, the selectivity of this drug is likely to be reduced at high
doses. Microdialysis studies have reported that the concentration of
extracellular noradrenaline and dopamine is increased in the prefrontal
cortex of mice following administration of either 1 or 3 mg/kg of this
drug (Koda et al., 2010) but no such increasewas reported for serotonin.
This disparity in monoamine responses suggests that, although
atomoxetine has a Ki for SERT that is only 10-fold higher than that for
the noradrenaline transporter, serotonin is unlikely to be directly
involved in the behavioural effects of this drug.4.3. Atomoxetine does not improve attention
Atomoxetine did not improve either measure of attention
(%omissions and %accuracy) in either genotype. There are isolated
reports that atomoxetine improves accuracy in rats (Baarendse and
Vanderschuren, 2012; Robinson, 2012) but, in general, %omissions
in the 5-CSRTT increase, rather than diminish, after atomoxetine
treatment (e.g. Baarendse and Vanderschuren, 2012; Sun et al.,
2012). However, inattentiveness is consistently reduced by
atomoxetine in clinical studies (Faraone and Glatt, 2010; Hazell
et al., 2011;Wilens et al., 2006), suggesting that this aspect of behav-
iour in the 5-CSRTTmight not translate reliably between rodents and
humans.5. Conclusions
The ﬁndings reported here are consistent with preclinical and
clinical evidence that atomoxetine causes a robust reduction in locomo-
tor hyperactivity and impulsivity, especially in animals that display a
high incidence of these behaviours. We believe that this is the ﬁrst
study to report that atomoxetine is more effective in mice that express
behavioural abnormalities in the 5-CSRTT that resemble those in
ADHD, when compared with their wildtypes. Our ﬁndings further lead
us to infer that atomoxetine would be most suitable for treating the
hyperactive–impulsive subtype of ADHD, particularly in a subset of
patients with TACR1 polymorphisms.Author contributions
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